These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21741090)

  • 21. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycaemic control with liraglutide: the phase 3 trial programme.
    Raskin P; Mora PF
    Int J Clin Pract Suppl; 2010 Oct; (167):21-7. PubMed ID: 20887301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
    Iltz JL; Baker DE; Setter SM; Keith Campbell R
    Clin Ther; 2006 May; 28(5):652-65. PubMed ID: 16861088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The design of the liraglutide clinical trial programme.
    Nauck MA
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():4-12. PubMed ID: 22405264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liraglutide: a review of its use in type 2 diabetes mellitus.
    Croom KF; McCormack PL
    Drugs; 2009 Oct; 69(14):1985-2004. PubMed ID: 19747013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*).
    Yang W; Chen L; Ji Q; Liu X; Ma J; Tandon N; Bhattacharyya A; Kumar A; Kim KW; Yoon KH; Bech OM; Zychma M
    Diabetes Obes Metab; 2011 Jan; 13(1):81-8. PubMed ID: 21114607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early clinical studies with liraglutide.
    Schmidt WE
    Int J Clin Pract Suppl; 2010 Oct; (167):12-20. PubMed ID: 20887300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.
    Gross B
    J Pharm Pract; 2013 Apr; 26(2):144-50. PubMed ID: 23204146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Nauck M; Frid A; Hermansen K; Shah NS; Tankova T; Mitha IH; Zdravkovic M; Düring M; Matthews DR;
    Diabetes Care; 2009 Jan; 32(1):84-90. PubMed ID: 18931095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    Thompson AM; Trujillo JM
    Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.
    Kumar A
    Expert Opin Biol Ther; 2014 Jun; 14(6):869-78. PubMed ID: 24702171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.
    Nauck M; Marre M
    Postgrad Med; 2009 May; 121(3):5-15. PubMed ID: 19491535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.
    Lindamood CA; Taylor JR
    Clin Ther; 2015 Mar; 37(3):483-93. PubMed ID: 25659912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liraglutide: from clinical trials to clinical practice.
    Gough SC
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.